# Oncology drug pricing and price transparency

Source: https://onco.cc/terms/drug-price-transparency/  
OnCo record `drug-price-transparency` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

New cancer drugs commonly launch above $150,000-$250,000 per year in the US, with prices set without reference to benefit and hidden behind rebates; other countries negotiate or assess cost-effectiveness. Pricing policy determines who gets treated.

## Summary

Median annual US launch price of new oncology drugs rose from ~$100,000 (2010) to over $200,000 (2020s), with weak correlation between price and clinical benefit (Vokinger, Lancet Oncol 2020). List versus net price (rebates, 340B) obscures costs; Medicare negotiation under the Inflation Reduction Act (2022) began with imbruvica (ibrutinib) among the first ten drugs (prices effective 2026) and caps Part D out-of-pocket at $2,000 (2025). Value frameworks: ASCO Value Framework, ESMO-MCBS, NCCN Evidence Blocks, ICER cost-effectiveness reviews, NICE thresholds (£25,000-35,000/QALY since 2 April 2026, raised from £20,000-30,000; Cancer Drugs Fund for managed access), Germany's AMNOG benefit assessment. International reference pricing, biosimilar/generic entry (imatinib price fell >90% after 2016 US generics), compulsory licensing and tiered pricing shape global access. Transparency initiatives (WHO 2019 resolution, US hospital price transparency rule) have had limited effect on net prices.

## Fields

- Kind: Term
- Last checked: 2026-09-08
- Tags: gap-fill; policy

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Prescription_drug_prices_in_the_United_States
- Vokinger 2020 price vs benefit (Lancet Oncol): https://doi.org/10.1016/S1470-2045(20)30139-X
- ICER: https://icer.org/
- CMS Medicare Drug Price Negotiation: https://www.cms.gov/inflation-reduction-act-and-medicare/medicare-drug-price-negotiation

## Connected records

- technologies: [Financial toxicity and financial navigation](https://onco.cc/technologies/financial-navigation/), [Global oncology and access in low- and middle-income countries](https://onco.cc/technologies/global-oncology-access/)
- terms: [340B Drug Pricing Program](https://onco.cc/terms/340b-program/), [Accelerated approval](https://onco.cc/terms/accelerated-approval/), [Biosimilar](https://onco.cc/terms/biosimilar/), [China National Reimbursement Drug List negotiation and volume-based procurement](https://onco.cc/terms/china-vbp-nrdl/), [Financial toxicity](https://onco.cc/terms/financial-toxicity/), [Health technology assessment (HTA), reimbursement and QALYs](https://onco.cc/terms/hta/), [Inflation Reduction Act 2022: Medicare drug price negotiation](https://onco.cc/terms/inflation-reduction-act/), [Nexavar compulsory licence (India, 2012)](https://onco.cc/terms/nexavar-compulsory-licence/), [Novartis v. Union of India (Glivec, 2013)](https://onco.cc/terms/novartis-glivec-ruling/), [WHO Essential Medicines List for cancer](https://onco.cc/terms/who-essential-medicines/)
- key papers: [Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis](https://onco.cc/key-papers/paper-vokinger-lancet-oncol/)
- ideas: [Extend Medicare's inflation rebates to employer plans](https://onco.cc/ideas/idea-cost-inflation-rebates-commercial/), [Transparent cost-plus pricing for every oral oncology generic](https://onco.cc/ideas/idea-cost-transparent-generic-pricing/)
- collections: [NICE cancer guidance and technology appraisals (UK)](https://onco.cc/collections/nice-guidance/)

---
JSON: https://onco.cc/api/v1/entities/drug-price-transparency.json